

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/684,383	10/10/2000	Helge Neidhardt	P100564-00030		
	590 07/01/2002	EXAMINER			
Arent Fox Kintner Plotkin & Kahn PLLC 1050 Connecticut Ave N W Suite 600 Washington, DC 20036-5339			MERTZ, PREMA MARIA		
			ART UNIT	PAPER NUMBER	
			1646 DATE MAILED: 07/01/2002	7	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)					
Office Action Summary		09/684,383		Hotten e	et al.			
		Examiner Prema Mertz		Art Unit 1646				
	The MAILING DATE of this communication appears	on the cover sheet wi	th the corre	spondence addi	ress			
Period for A SHO THE M - Extension mailing of the period o		in no event, however, may a ret the statutory minimum of thirty y and will expire \$1X (6) MONTI	MONTI oly be timely filed (30) days will be 15 from the mail NDONED (35 U.	H(S) FROM d after SIX (6) MONT be considered timely. ing date of this community. S.C. § 133).	THS from the			
Status 1) ☑	Responsive to communication(s) filed on Jun 4, 2	2002			·			
2-1	This action is FINAL 2b) 🔀 This a	ction is non-final.						
2a) ☐ 3) ☐	This action is the condition for allowance except for formal matters, prosecution as to the merits is							
Disposit	tion of Claims		ie/a	re nendina in 1	the application.			
4) 💢	claim(s) <u>24-28</u>			to be discovered	tram consideration			
4	a) Of the above, claim(s)		IS/	are withdrawii	HOIN CONSIDERATION			
E\ [Claim(s)			_ 15/416 4110				
6) 🗆	Claim(s)			_ 15/8/6 / 6/600	tad ta			
	m 1 - (-)			_ 13/010 00/00	•••			
8) 💢	Claim(s)	are sub	ject to rest	riction and/or	election requirement.			
Applica	ation Papers							
9) 🗆	the Everniner			-t-d to by the	Evaminer			
10)□	The drawing(s) filed onis/	fare a) ☐ accepted o	r b)∟ obje	Cted to by the	R5(a)			
	Applicant may not request that any objection to the three proposed drawing correction filed on							
11)	The proposed drawing correction filed on).					
	If approved, corrected drawings are required in re	rominer						
	The oath or declaration is objected to by the Ex	annici.						
Priorit	y under 35 U.S.C. §§ 119 and 120 Acknowledgement is made of a claim for foreig	n priority under 35 U	.S.C. § 119	3(a)-(d) or (f).				
13)∟	Acknowledgement is made of a claim to total	,						
a)	☐ All b) ☐ Some* c) ☐ None of:1. ☐ Certified copies of the priority documents	have been received.						
	- designation	have been received i	n Applicatio	on No	•			
	3. Copies of the certified copies of the priori	ity documents have b Bureau (PCT Rule 17.	een receive 2(a)).	g in this Mano	nal Stage			
*	See the attached detailed Office action for a list of	oetic oriority under 3F	S.C. § 1	I 19(e).				
14)[Acknowledgement is made of a claim for dome	estic priority under Sc	been receiv	ved.				
	The translation of the foreign language provided Acknowledgement is made of a claim for domination.	estic priority under 35	U.S.C. §§	120 and/or 1	21.			
15)[outo priority arrest of						
	hment(s) Notice of References Cited (PTO-892)	4) 🔲 Interview Summ	nary (PTO-413)	Paper No(s)	_			
I " L	Horizon of Figure and Control of the		1 D 4 4 A	ertica (PTO-152)				

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

6) Other:

5) Notice of Informal Patent Application (PTO-152)

Application/Control Number: 09/684,383

Art Unit: 1646

DETAILED ACTION

Page 2

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 24-28, are drawn to an polypeptide of SEQ ID NO:2 and a pharmaceutical composition thereof, classified in Class 424, subclass 85.1.

Group II. Claims 24-28, are drawn to an polypeptide of SEQ ID NO:4 and a pharmaceutical composition thereof, classified in Class 424, subclass 85.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-II are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention which cannot be exchanged. The proteins of inventions I-II can be used as probes, or used therapeutically or diagnostically, e.g. in screening, or as probes in immunoassays. Furthermore, each of the polypeptides are materially different products which are structurally and chemically different, capable of separate manufacture and use. The products in the different Groups are physically and chemically distinct from each other, and if patentable would support separate patents. Distinctness is further shown because a search of one of the polypeptides would not reveal art pertinent to the other and each of these products can be made and used without any one or more of the other products. Separate searches would be required for searching each of the polypeptide products eg. a search of the literature for the polypeptide of SEQ ID NO:2 would not necessarily reveal art for the polypeptide of SEQ ID NO:4. Therefore, each of the polypeptides

Application/Control Number: 09/684,383

Art Unit: 1646

are not related and are properly restrictable in accordance with MPEP.. § 806.04 and MPEP.. § 808.01.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter as defined by MPEP... § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP... § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (703) 308-4229. The examiner can normally be reached on Monday-Friday from 8:00AM to 4:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4227. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Art Unit: 1646

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 June 10, 2002